Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: A review from a clinical perspective

José M. Climent, Da-Shen Kuan, Pedro Fenollosa, Francisco Martin-Del-Rosario

研究成果: Review article

11 引文 (Scopus)

摘要

Introduction. Botulinum toxin inhibits acetylcholine (ACh) release and probably blocks some nociceptive neurotransmitters. It has been suggested that the development of myofascial trigger points (MTrP) is related to an excess release of ACh to increase the number of sensitized nociceptors. Although the use of botulinum toxin to treat myofascial pain syndrome (MPS) has been investigated in many clinical trials, the results are contradictory. The objective of this paper is to identify sources of variability that could explain these differences in the results. Material and Methods. We performed a content analysis of the clinical trials and systematic reviews of MPS. Results and Discussion. Sources of differences in studies were found in the diagnostic and selection criteria, the muscles injected, the injection technique, the number of trigger points injected, the dosage of botulinum toxin used, treatments for control group, outcome measures, and duration of followup. The contradictory results regarding the efficacy of botulinum toxin A in MPS associated with neck and back pain do not allow this treatment to be recommended or rejected. There is evidence that botulinum toxin could be useful in specific myofascial regions such as piriformis syndrome. It could also be useful in patients with refractory MPS that has not responded to other myofascial injection therapies.

原文English
文章編號381459
期刊Evidence-based Complementary and Alternative Medicine
2013
DOIs
出版狀態Published - 2013 三月 15

指紋

Myofascial Pain Syndromes
Botulinum Toxins
Neck
Trigger Points
Acetylcholine
Piriformis Muscle Syndrome
Clinical Trials
Intractable Pain
Nociceptors
Type A Botulinum Toxins
Injections
Neck Pain
Therapeutics
Back Pain
Patient Selection
Neurotransmitter Agents
Outcome Assessment (Health Care)
Muscles
Control Groups

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

引用此文

@article{9ca619fc3deb41daab9be377af90ee32,
title = "Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: A review from a clinical perspective",
abstract = "Introduction. Botulinum toxin inhibits acetylcholine (ACh) release and probably blocks some nociceptive neurotransmitters. It has been suggested that the development of myofascial trigger points (MTrP) is related to an excess release of ACh to increase the number of sensitized nociceptors. Although the use of botulinum toxin to treat myofascial pain syndrome (MPS) has been investigated in many clinical trials, the results are contradictory. The objective of this paper is to identify sources of variability that could explain these differences in the results. Material and Methods. We performed a content analysis of the clinical trials and systematic reviews of MPS. Results and Discussion. Sources of differences in studies were found in the diagnostic and selection criteria, the muscles injected, the injection technique, the number of trigger points injected, the dosage of botulinum toxin used, treatments for control group, outcome measures, and duration of followup. The contradictory results regarding the efficacy of botulinum toxin A in MPS associated with neck and back pain do not allow this treatment to be recommended or rejected. There is evidence that botulinum toxin could be useful in specific myofascial regions such as piriformis syndrome. It could also be useful in patients with refractory MPS that has not responded to other myofascial injection therapies.",
author = "Climent, {Jos{\'e} M.} and Da-Shen Kuan and Pedro Fenollosa and Francisco Martin-Del-Rosario",
year = "2013",
month = "3",
day = "15",
doi = "10.1155/2013/381459",
language = "English",
volume = "2013",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back : A review from a clinical perspective. / Climent, José M.; Kuan, Da-Shen; Fenollosa, Pedro; Martin-Del-Rosario, Francisco.

於: Evidence-based Complementary and Alternative Medicine, 卷 2013, 381459, 15.03.2013.

研究成果: Review article

TY - JOUR

T1 - Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back

T2 - A review from a clinical perspective

AU - Climent, José M.

AU - Kuan, Da-Shen

AU - Fenollosa, Pedro

AU - Martin-Del-Rosario, Francisco

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Introduction. Botulinum toxin inhibits acetylcholine (ACh) release and probably blocks some nociceptive neurotransmitters. It has been suggested that the development of myofascial trigger points (MTrP) is related to an excess release of ACh to increase the number of sensitized nociceptors. Although the use of botulinum toxin to treat myofascial pain syndrome (MPS) has been investigated in many clinical trials, the results are contradictory. The objective of this paper is to identify sources of variability that could explain these differences in the results. Material and Methods. We performed a content analysis of the clinical trials and systematic reviews of MPS. Results and Discussion. Sources of differences in studies were found in the diagnostic and selection criteria, the muscles injected, the injection technique, the number of trigger points injected, the dosage of botulinum toxin used, treatments for control group, outcome measures, and duration of followup. The contradictory results regarding the efficacy of botulinum toxin A in MPS associated with neck and back pain do not allow this treatment to be recommended or rejected. There is evidence that botulinum toxin could be useful in specific myofascial regions such as piriformis syndrome. It could also be useful in patients with refractory MPS that has not responded to other myofascial injection therapies.

AB - Introduction. Botulinum toxin inhibits acetylcholine (ACh) release and probably blocks some nociceptive neurotransmitters. It has been suggested that the development of myofascial trigger points (MTrP) is related to an excess release of ACh to increase the number of sensitized nociceptors. Although the use of botulinum toxin to treat myofascial pain syndrome (MPS) has been investigated in many clinical trials, the results are contradictory. The objective of this paper is to identify sources of variability that could explain these differences in the results. Material and Methods. We performed a content analysis of the clinical trials and systematic reviews of MPS. Results and Discussion. Sources of differences in studies were found in the diagnostic and selection criteria, the muscles injected, the injection technique, the number of trigger points injected, the dosage of botulinum toxin used, treatments for control group, outcome measures, and duration of followup. The contradictory results regarding the efficacy of botulinum toxin A in MPS associated with neck and back pain do not allow this treatment to be recommended or rejected. There is evidence that botulinum toxin could be useful in specific myofascial regions such as piriformis syndrome. It could also be useful in patients with refractory MPS that has not responded to other myofascial injection therapies.

UR - http://www.scopus.com/inward/record.url?scp=84874857301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874857301&partnerID=8YFLogxK

U2 - 10.1155/2013/381459

DO - 10.1155/2013/381459

M3 - Review article

C2 - 23533477

AN - SCOPUS:84874857301

VL - 2013

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 381459

ER -